Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Polymeric delivery formulations of leuprolide with improved efficacy|
|Abstract:||The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.|
|Inventor(s):||Dunn; Richard L. (Fort Collins, CO), Garrett; John Steven (Fort Collins, CO), Ravivarapu; Harish (Union City, CA), Chandrashekar; Bhagya L. (Fort Collins, CO)|
|Assignee:||Tolmar Therapeutics, Inc. (Fort Collins, CO)|
|Filing Date:||May 20, 2010|
|Claims:||1. A flowable composition suitable for use as a controlled release implant, the composition comprising: (a) a biodegradable thermoplastic copolymer of lactide and glycolide including a diol residue, wherein the copolymer has a weight average molecular weight of about 15,000 to about 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate in an amount sufficient to reduce LHRH levels in a human. |
2. The flowable composition of claim 1, wherein the diol residue is included as a chain extender.
3. The flowable composition of claim 1, wherein the diol is 1,6-hexanediol.
4. A biodegradable implant formed in situ, in a patient, by the steps comprising: (a) injecting the flowable composition of claim 1 within the body of the patient; and (b) allowing the N-methyl-2-pyrrolidone to dissipate to produce a solid, biodegradable implant.
5. A method of reducing serum testosterone levels in a human comprising injecting a flowable composition comprising: (a) a biodegradable thermoplastic copolymer of lactide and glycolide including a diol residue, wherein the copolymer has a weight average molecular weight of about 15,000 to about 45,000; (b) N-methyl-2-pyrrolidone; and (c) leuprolide acetate in an amount sufficient to reduce LHRH levels in a human; wherein the flowable composition is injected within a body tissue of the human so that the N-methyl-2-pyrrolidone diffuses in the body fluid of the human to cause precipitation of the copolymer of lactide and glycolide to form an in situ solid implant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.